Hubert Department of Global Health, Rollins School of Public Health, and Center for Ethics, Emory University, Atlanta, Georgia, United States of America.
National Ambulance Center, Ministry of Public Health and Population, Port-au-Prince, Haiti.
PLoS Negl Trop Dis. 2020 May 29;14(5):e0008318. doi: 10.1371/journal.pntd.0008318. eCollection 2020 May.
The World Health Organization (WHO) defines an effective round of mass drug administration (MDA) for lymphatic filariasis (LF) as one that reaches at least 65% of the target population. In its first round of MDA in 2011-2012, the National Program to Eliminate LF in Haiti achieved a 79% epidemiological coverage in urban Port-au-Prince. In 2013, coverage dropped below the WHO threshold and has declined year-over-year to a low of 41% in 2017. We conducted a retrospective qualitative case study to identify key factors behind the decline in coverage in Port-au-Prince and ways to address them. Our findings suggest that the main contributors to the decline in MDA coverage appear to be the absence of effective documentation of practices, reporting, analysis, and program quality improvement-i.e., learning mechanisms-within the program's MDA design and implementation strategy. In addition to their contribution to the program's failure to meet its coverage targets, these deficits have resulted in a high cost for the MDA campaign in both lost momentum and depleted morale. Through a proposed operating logic model, we explore how the pathway from program inputs to outcomes is influenced by a wide array of mediating factors, which shape potential participants' experience of MDA and, in turn, influence their reasoning and decisions to take, or not take, the pills. Our model suggests that the decisions and behavior of individuals are a reflection of their overall experience of the program itself, mediated through a host of contextual factors, and not simply the expression of a fixed choice or preference. This holistic approach offers a novel and potentially valuable framing for the planning and evaluation of MDA strategies for LF and other diseases, and may be applicable in a variety of global health programs.
世界卫生组织(WHO)将有效大规模药物治疗(MDA)定义为覆盖至少 65%目标人群的一轮治疗。在海地国家消除淋巴丝虫病规划于 2011-2012 年开展的首轮 MDA 中,太子港城市地区的流行病学覆盖率达到了 79%。2013 年,覆盖率低于世卫组织的阈值,并逐年下降,2017 年降至 41%的历史最低点。我们开展了一项回顾性定性案例研究,以确定太子港覆盖率下降的关键因素以及解决这些问题的方法。研究结果表明,导致 MDA 覆盖率下降的主要因素似乎是方案中 MDA 设计和实施策略缺乏有效记录实践、报告、分析和方案质量改进的情况,即学习机制。除了导致方案未能实现覆盖目标外,这些缺陷还导致 MDA 运动在失去动力和士气低落方面付出了高昂的代价。通过提出的运行逻辑模型,我们探讨了从方案投入到产出的路径如何受到广泛的中介因素的影响,这些因素塑造了潜在参与者对 MDA 的体验,进而影响他们接受或拒绝服药的理由和决策。我们的模型表明,个人的决策和行为反映了他们对方案本身的整体体验,这是通过一系列的背景因素来调解的,而不仅仅是表达一种固定的选择或偏好。这种整体方法为规划和评估 LF 及其他疾病的 MDA 策略提供了一个新颖且有潜在价值的框架,并且可能适用于各种全球卫生计划。